Payment overview · 2025
General Payments
$2,057.88
80 reported records · 20 companies
Healthcare provider profile · identity verified
Arie Szatkowski, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · MEMPHIS, TN · NPI 1356443451
Verified facts
What the public records show
CMS Open Payments records show Arie Szatkowski, MD received $2,057.88 in general payments during 2025 across 80 reported records.
HEARTFLOW, INC. accounted for 11.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic, Verquvo, Wegovy.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 593 claims for Jardiance by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERQUVO as an associated drug or biological on 38060 records involving 12268 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Verquvo by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 661 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 1428 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $244.65 | 11.9% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $243.23 | 11.8% | 11 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $179.63 | 8.7% | 10 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$167.78 | 8.2% | 7 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $165.63 | 8.1% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $160.54 | 7.8% | 9 | 2025 |
| BIOTRONIK INC. | Unresolved — no canonical attribution shown | $144.01 | 7.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $127.38 | 6.2% | 5 | 2025 |
| Kaneka Medical America LLC | Unresolved — no canonical attribution shown | $123.01 | 6.0% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $109.02 | 5.3% | 7 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $103.28 | 5.0% | 6 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $77.41 | 3.8% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $49.40 | 2.4% | 3 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $35.01 | 1.7% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $27.41 | 1.3% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $21.36 | 1.0% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $20.88 | 1.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.23 | 1.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.27 | 0.9% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $18.75 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,052.88 | 79 |
| Travel and Lodging | $5.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $244.65 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $243.23 | 11 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $179.63 | 10 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $165.63 | 7 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $160.54 | 9 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $147.73 | 6 | 2025 |
Source payment records
|
|||||
| AMVIA EDGE Normalized: amvia edge |
Device | BIOTRONIK INC. | $144.01 | 1 | 2025 |
Source payment records
|
|||||
| Acticor 7 VR-T DX Normalized: acticor 7 vr t dx |
Device | BIOTRONIK INC. | $144.01 | 1 | 2025 |
Source payment records
|
|||||
| BIOMONITOR Normalized: biomonitor |
Device | BIOTRONIK INC. | $144.01 | 1 | 2025 |
Source payment records
|
|||||
| PAMIRA Normalized: pamira |
Device | BIOTRONIK INC. | $144.01 | 1 | 2025 |
Source payment records
|
|||||
| Solia Normalized: solia |
Device | BIOTRONIK INC. | $144.01 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $141.27 | 6 | 2025 |
Source payment records
|
|||||
| Apheresis Machine Normalized: apheresis machine |
Device | Kaneka Medical America LLC | $123.01 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $109.02 | 7 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $103.28 | 6 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $77.41 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $71.60 | 3 | 2025 |
Source payment records
|
|||||
| OPSYNVI Normalized: opsynvi |
Drug | Actelion Pharmaceuticals US, Inc. | $55.89 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $55.78 | 2 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $49.40 | 3 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $42.53 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $35.01 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $27.41 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $21.36 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $20.88 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $20.23 | 1 | 2025 |
Source payment records
|
|||||
| AURORA EV-ICD MRI SURESCAN Normalized: aurora ev icd mri surescan |
Device | Medtronic, Inc. | $20.05 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $19.27 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.27 | 1 | 2025 |
Source payment records
|
|||||
| Ambulatory Monitoring & Diagnostics Undivided Normalized: ambulatory monitoring diagnostics undivided |
Device | Philips North America LLC | $18.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 1428 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 593 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 36 | exact normalized | Medicare Part D |
| VERQUVO verquvo |
2025 | Verquvo | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
94 | 22 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
116 | 33 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
593 | 136 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VERQUVO open payments reported associated product |
CMS Open Payments — General Payments 38060 supporting records · 12268 recipient NPIs · example record 1237992208 |
Verquvo · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
661 | 143 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
36 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1428 | 305 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Eliquis | Apixaban | 1428 | 305 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1289 | 386 |
| Carvedilol | Carvedilol | 1224 | 351 |
| Amlodipine Besylate | Amlodipine Besylate | 1205 | 374 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1091 | 330 |
| Spironolactone | Spironolactone | 917 | 259 |
| Furosemide | Furosemide | 844 | 286 |
| Metoprolol Tartrate | Metoprolol Tartrate | 721 | 212 |
| Metoprolol Succinate | Metoprolol Succinate | 691 | 203 |
| Entresto | Sacubitril/Valsartan | 661 | 143 |
| Lisinopril | Lisinopril | 619 | 175 |
| Losartan Potassium | Losartan Potassium | 614 | 186 |
| Jardiance | Empagliflozin | 593 | 136 |
| Clopidogrel | Clopidogrel Bisulfate | 525 | 160 |
| Valsartan | Valsartan | 483 | 137 |
| Ezetimibe | Ezetimibe | 433 | 135 |
| Hydralazine Hcl | Hydralazine Hcl | 431 | 145 |
| Potassium Chloride | Potassium Chloride | 360 | 109 |
| Warfarin Sodium | Warfarin Sodium | 353 | 90 |
| Amiodarone Hcl | Amiodarone Hcl | 344 | 117 |
| Xarelto | Rivaroxaban | 326 | 76 |
| Simvastatin | Simvastatin | 272 | 76 |
| Hydrochlorothiazide | Hydrochlorothiazide | 267 | 86 |
| Repatha Sureclick | Evolocumab | 261 | 53 |
| Fenofibrate | Fenofibrate | 226 | 65 |
| Sotalol | Sotalol Hcl | 213 | 54 |
| Omeprazole | Omeprazole | 208 | 65 |
| Pravastatin Sodium | Pravastatin Sodium | 205 | 59 |
| Pantoprazole Sodium | Pantoprazole Sodium | 201 | 64 |
| Flecainide Acetate | Flecainide Acetate | 200 | 51 |
| Chlorthalidone | Chlorthalidone | 199 | 55 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 132 | 50 |
| Farxiga | Dapagliflozin Propanediol | 116 | 33 |
| Irbesartan | Irbesartan | 102 | 28 |
| Bumetanide | Bumetanide | 101 | 36 |
| Gabapentin | Gabapentin | 100 | 35 |
| Clonidine Hcl | Clonidine Hcl | 96 | 39 |
| Brilinta | Ticagrelor | 94 | 22 |
| Nitroglycerin | Nitroglycerin | 92 | 48 |
| Escitalopram Oxalate | Escitalopram Oxalate | 90 | 23 |
| Fenofibrate | Fenofibrate Nanocrystallized | 87 | 22 |
| Benazepril Hcl | Benazepril Hcl | 83 | 28 |
| Ranolazine Er | Ranolazine | 83 | 29 |
| Vascepa | Icosapent Ethyl | 81 | 25 |
| Ramipril | Ramipril | 76 | 22 |
| Praluent Pen | Alirocumab | 75 | 12 |
| Metformin Hcl | Metformin Hcl | 74 | 26 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 73 | 25 |
| Levothyroxine Sodium | Levothyroxine Sodium | 71 | 25 |
| Midodrine Hcl | Midodrine Hcl | 71 | 31 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 71 | 23 |
| Atenolol | Atenolol | 65 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 65 | 22 |
| Alprazolam | Alprazolam | 63 | 16 |
| Famotidine | Famotidine | 62 | 21 |
| Sertraline Hcl | Sertraline Hcl | 59 | 17 |
| Repatha Syringe | Evolocumab | 55 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 54 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 52 | 18 |
| Allopurinol | Allopurinol | 51 | 17 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 45 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 45 | 14 |
| Clonidine | Clonidine | 43 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 42 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 40 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 39 | 13 |
| Cilostazol | Cilostazol | 37 | suppressed |
| Ozempic | Semaglutide | 36 | 16 |
| Meloxicam | Meloxicam | 35 | suppressed |
| Sotalol Af | Sotalol Hcl | 34 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 32 | suppressed |
| Glipizide | Glipizide | 32 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 32 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 32 | 13 |
| Torsemide | Torsemide | 32 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | 16 |
| Diltiazem Hcl | Diltiazem Hcl | 29 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 28 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 27 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 26 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 26 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 25 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 23 | suppressed |
| Digoxin | Digoxin | 22 | suppressed |
| Magnesium Sulfate | Magnesium Sulfate | 22 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 21 | 12 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Methylprednisolone | Methylprednisolone | 21 | 17 |
| Tramadol Hcl | Tramadol Hcl | 20 | suppressed |
| Metolazone | Metolazone | 18 | suppressed |
| Multaq | Dronedarone Hcl | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Prednisone | Prednisone | 17 | suppressed |
| Azithromycin | Azithromycin | 16 | 15 |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 16 | suppressed |
| Eplerenone | Eplerenone | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Wegovy | Semaglutide | 15 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 11 |
| Droxidopa | Droxidopa | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Verquvo | Vericiguat | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Edarbi | Azilsartan Medoxomil | 11 | suppressed |
| Niacin Er | Niacin | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
| Verapamil Sr | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,057.88 · 80 records | HEARTFLOW, INC. | AMVIA EDGE, AMVUTTRA, AURORA EV-ICD MRI SURESCAN, Acticor 7 VR-T DX, Ambulatory Monitoring & Diagnostics Undivided, Apheresis Machine, BIOMONITOR, CAPVAXIVE, ELIQUIS, FFRct, INJECTAFER, INSPIRE, JARDIANCE, Kerendia, LEQVIO, LifeVest, NEXLETOL, NURTEC ODT, OPSUMIT, OPSYNVI, Ozempic, PAMIRA, REPATHA, SYMPLICITY G3, Solia, UPTRAVI, VERQUVO, WAINUA, WATCHMAN FLX, Wegovy | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error